Intensive Glucose Targets: No Mortality Gain, 3.6-Fold Hypoglycemia Risk

This updated meta-analysis incorporating TGC-Fast confirms that intensive glycemic targets do not improve ICU or hospital mortality and substantially increase severe hypoglycemia, reinforcing conservative insulin infusion practice for ICU pharmacists.

insulinintensive glucose controlconventional glucose controlhyperglycemiahypoglycemiacritical illnessglycemic controlmeta-analysisSCCM guidelinesTGC-FastICU Critical Care / ICU

Background Information

Intensive glycemic control cuts morbidity but triples hypoglycemia risk.

Glycemic control in critically ill adults is crucial for balancing morbidity outcomes and avoiding severe hypoglycemia. Intensive blood glucose control reduced ICU length of stay, infections, and critical illness polyneuropathy, but increased severe hypoglycemia risk by 3.6 times without affecting mortality. Intensive targets should be avoided unless hypoglycemia risk is minimal; select centers may use these targets with optimal protocols. Intensive glycemic control improves morbidity but risks hypoglycemia, so conventional targets are safer.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Sirimaturos M, Honarmand K, Long MT, Preiser JC, Nagpal AD, Agus MSD, Aldouhan J, Bircher NG, Carpenter DL, Dearness K, Farrington EA, Freire AX, Hirshberg EL, Irving SY, Krinsley JS, Lanspa MJ, Prager R, Srinivasan V, Umpierrez GE, Wax SP, Jacobi J

Citation: Sirimaturos M, Honarmand K, Long MT, et al. Comparison of Intensive Versus Conventional Glycemic Control Targets: An Updated Systematic Review and Meta-Analysis of the 2024 Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Adults. Critical care medicine. 2026. doi:10.1097/CCM.0000000000007175

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →